Black Diamond Therapeutics (BDTX) EBT (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly EBT came in at -$11.4 million in Q1 2026, down 121.06% YoY from $54.0 million in Q1 2025, and up 35.24% on a QoQ basis from -$17.6 million in Q4 2025.
Black Diamond Therapeutics (BDTX) EBT (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of EBT data on file, last reported at -$11.4 million in Q1 2026.
- Quarterly EBT fell 121.06% year-over-year to -$11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 43.98% YoY) and the FY2025 annual result came in at -$107.6 million, up 47.28% from the prior year.
- EBT climbed to -$11.4 million in Q1 2026, from -$17.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of $54.0 million in Q1 2025 to a low of -$57.3 million in Q3 2022.
- A 5-year average of -$22.5 million and a median of -$22.0 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT soared 361.09% — and 2026, when it tumbled 121.06%.
- Tracing BDTX's EBT over 5 years: stood at -$22.2 million in 2022, then gained by 2.77% to -$21.6 million in 2023, then increased by 12.92% to -$18.8 million in 2024, then increased by 6.66% to -$17.6 million in 2025, then jumped by 35.24% to -$11.4 million in 2026.
- The last three EBT figures came in at -$11.4 million (Q1 2026), -$17.6 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 81.49 Mn |
| 10 | Black Diamond Therapeutics | 126.21 Mn | 15.70 Mn | - | -11.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.26 Mn |
| Mar 31, 2026 | -11.38 Mn |
| Dec 31, 2025 | -17.57 Mn |
| Sep 30, 2025 | -15.33 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Mar 31, 2025 | 54.02 Mn |
| Dec 31, 2024 | -18.82 Mn |
| Sep 30, 2024 | -24.98 Mn |
| Jun 30, 2024 | -49.92 Mn |
| Mar 31, 2024 | -20.69 Mn |
| Dec 31, 2023 | -21.61 Mn |
| Sep 30, 2023 | -55.06 Mn |
| Jun 30, 2023 | -30.81 Mn |
| Mar 31, 2023 | -21.99 Mn |
| Dec 31, 2022 | -22.23 Mn |
| Sep 30, 2022 | -57.27 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -25.98 Mn |
| Dec 31, 2021 | -26.10 Mn |
| Sep 30, 2021 | -43.00 Mn |